Selected Abstracts

Metabolomics of cerebrospinal fluid from progressive MS patients

F Mir, D Lee, H Ray, SA Sadiq. Presented at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston, September 10-13, 2014. Accepted for presentation at the Society for Neuroscience meeting in Washington, DC, November 15-19, 2014.

Read Abstract

CSF fetuin-A is a biomarker of subclinical disease activity in progressive MS

VK Harris, M Landy, S Chirls, I Londono, SA Sadiq. Presented at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston, September 10-13, 2014.

Read Abstract

TGM6 is highly expressed by reactive astrocytes in the murine spinal cord during EAE and its levels correlate with the disease course

M Cristofanilli, D Gratch, B Pagano, SA Sadiq. Presented at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston, September 10-13, 2014. Accepted for presentation at the Society for Neuroscience meeting in Washington, DC, November 15-19, 2014.

Read Abstract

The protection of A2aR on BBB permeability from Th1 cytokines in MS

M Alahiri, S Agarwal, SA Sadiq, Y Liu. Presented at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston, September 10-13, 2014.

Exosomes released by mesenchymal stem cell populations promote differentiation and maturation of oligodendrocytes

M Landy, VK Harris, SA Sadiq. Presented at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston, September 10-13, 2014.

Read Abstract

Intrathecal administration of mesenchymal stem cell-neural progenitors in multiple sclerosis: an interim analysis of a phase I clinical trial

VK Harris, T Vyshkina, S Chirls, SA Sadiq. Presented at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston, September 10-13, 2014.

Cerebrospinal fluid derived from progressive multiple sclerosis patients induces demyelinating lesions in the mouse CNS

M. Cristofanilli, B. Cymring, H. Rosenthal, B. Xie, S.A. Sadiq; Presented Nov. 11, 2013 at the 2013 annual Society for Neuroscience Conference.

Persistence of Cerebrospinal Fluid Oligoclonal Bands after Natalizumab Treatment of Multiple Sclerosis Patients

J.W. Stark, D. Koffler, and S.A. Sadiq. Presented at the 65th annual meeting of the American Academy of Neurology, held March 16-23, 2013 in San Diego, CA.

Read Abstract

Pages

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.